medigraphic.com
ISSN 1561-2937 (Print)

2014, Number 4

<< Back Next >>

Rev Cubana Cardiol Cir Cardiovasc 2014; 20 (4)

C-reactive protein (CRP) and the classic risk factors in patients with stable coronary artery disease

Heres ÁFC, Peix GA, Bacallao GJ, González GO, Ravelo DR, Soto MJ, Flores SA

Language: Spanish
References: 35
Page: 217-225
PDF size: 402.14 Kb.


ABSTRACT

Introduction: C-reactive protein (CRP) has emerged as an important indicator of risk for cardiovascular disease. Its predictive capacity could be linked to its relation with the cardiovascular risk factors.
Objetive: To identify the relationship between C-reactive protein levels and the cardiovascular classic risk factors in patients with stable coronary artery disease.
Methods: A total of 189 patients with angiographically determined stable coronary artery disease were studied. Sex, body mass index, smoking, hypertension, diabetes mellitus, lipids and CRP were evaluated. The CRP levels were determined by a high sensitive method.
Results: The CRP values were higher in women as compared to men (3.25 vs. 2.25 mg/L). Although the CRP values were higher when either cardiovascular risk factor was present, the most remarkable difference was for obese patients (3.88 vs. 1.54 mg/L). Positive correlations were observed both between CRP and body mass index (r = 0.191, p= 0.003) and CRP and triglycerides concentrations (r= 0.138, p=0.033), whereas a negative correlation was observed between CRP and HDL cholesterol (r= -0.150, p= 0.026). CRP levels increased with the increasing number of cardiovascular risk factors.
Conclusions: Higher C-reactive protein levels are related to female sex and to classic cardiovascular risk factors, mainly obesity and dislipidemia, in patients with stable coronary artery disease.


REFERENCES

  1. Libby P. Ridker PM, Hansson GK, Maseri A. Inflammation and atherosclerosis. Circulation. 2002; 105:1135-43.

  2. Golia E, Limongelli G, Natale F, Fimiani F, Maddaloni V, Russo PE, et al. Adipose tissue and vascular inflammation in coronary artery disease. World J Cardiol. 2014; 6: 539–54.

  3. Libby P, Tabas I, Fredman G, Fisher EA . Inflammation and its resolution as determinants of acute coronary syndromes. Circ Res. 2014; 114:1867-79.

  4. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, Criqui M, et al. Markers of inflammation and cardiovascular disease: Application to clinical and public health practice. A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003; 107:499-511.

  5. Ridker PM. C-reactive protein: eighty years from discovery to emergence as a major risk marker for cardiovascular disease. Clin Chem. 2009; 55: 209-15.

  6. Kaptoge S, Di Angelantonio E, Pennells L, Wood AM, White IR, Gao P, et al. C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med. 2012; 367:1310–20.

  7. Koenig W. High-sensitivity C-reactive protein and atherosclerotic disease: from improved risk prediction to risk-guided therapy. Int J Cardiol. 2013; 168:5126-34.

  8. Strang F, Schunkert H. C-Reactive Protein and Coronary Heart Disease: All Said—Is Not It? Mediators Inflamm. 2014; vol. 2014, Article ID 757123, 7 pages. Disponible: http://dx.doi.org/10.1155/2014/757123. [Consultado 22/9/2014].

  9. Heres-Álvarez F, Peix-González A. La proteína C reactiva como blanco terapéutico en la prevención cardiovascular: ¿ficción o realidad? Rev Esp Cardiol. 2011; 11 Supl E: 30–5.

  10. The Emerging Risk Factors Collaboration, Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, Collins R, et al: Creactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet. 2010; 375:132-40.

  11. Jeemon P, Prabhakaran D, Ramakrishnan L, Gupta R, Ahmed F, Thankappan KR, et al. Association of high sensitive C-reactive protein (hsCRP) with established cardiovascular risk factors in the Indian population. Nutr Metabolism. 2011; 8:19. Disponible: http://www.nutritionandmetabolism.com/content/8/1/19. [Consultado 22/9/2014].

  12. Halcox JP, Roy C, Tubach F, Banegas JR, Dallongeville J, De Backer G, et al. C-reactive protein levels in patients at cardiovascular risk: EURIKA study. BMC Cardiovasc Disord. 2014; 14:25. Disponible: http://www.biomedcentral.com/1471-2261/14/25. [Consultado 22/9/2014].

  13. Fernández-Berges D, Consuegra-Sánchez L, Peñafiel J, Cabrera de Leon A, Vila J, Felix-Redondo FJ, et al. Perfil metabólicoinflamatorio en la transición obesidad, síndrome metabólico y diabetes mellitus en población mediterránea. Estudio DARIOS Inflamatorio. Rev Esp Cardiol. 2014; 67:624–31.

  14. Klisic AN, Vasiljevic ND, Simic TP, Djukic TI, Maksimovic MZ, Matic MG. Association between C-reactive protein, anthropometric and lipid parameters among healthy normal weight and overweight postmenopausal women in Montenegro. Lab Medicine. 2014; 45: 12-16.

  15. Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, Dallongeville J, et al. Guías de práctica clínica sobre prevención de la enfermedad cardiovascular: versión resumida. Rev Esp Cardiol. 2008; 61:1-49.

  16. García-Moll X, Zouridakis E, Cole D, Kaski JC. C-reactive protein in patients with chronic stable angina: differences in baseline serum concentration between women and men. Eur Heart J. 2000; 21:1598–1606.

  17. Choi J, Joseph L, Pilote L. Obesity and C-reactive protein in various populations: a systematic review and meta-analysis. Obesity Rev. 2013; 14: 232–44.

  18. Khera A, McGuire D, Murphy S, Stanek H, Das S, Vongpatanasin W, et al. Race and gender differences in C-reactive protein levels. J Am Coll Cardiol. 2005; 46:464-9.

  19. Shaffer LE. Analysis of factors affecting the sex difference in Creactive protein levels. 2009. Tesis Doctoral. The Ohio State University. Disponible: http://rave.ohiolink.edu/etdc/view?acc_num=osu1243253719 [Consultado 22/4/2013].

  20. Sabatine MS, Morrow DA, Jablonski KA, Rice MM, Warnica JW, Domanski MJ, et al., for the PEACE Investigators. Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease. Circulation. 2007; 115:1528-36.

  21. Veselka J, Procházková S, Duchonová R, Bolomová I, Urbanová T, Tesar D. Relationship of C-reactive protein to adverse cardiovascular events in patients treated by percutaneous coronary intervention. Int Heart J. 2005; 46:195-204.

  22. Tataru MC, Heinrich J, Junker R, Schulte H, Von Eckardstein A, Assmann G, et al. C-reactive protein and the severity of atherosclerosis in myocardial infarction patients with stable angina pectoris. Eur Heart J. 2000; 21:1000–08.

  23. Gupta S, Gupta VK, Gupta R, Arora S, Gupta V. Relationship of high-sensitive C-reactive protein with cardiovascular risk factors, clinical presentation and angiographic profile in patients with acute coronary syndrome: An Indian perspective. Indian Heart J. 2013; 65: 359-65.

  24. Tonstad S, Cowan JL.C-reactive protein as a predictor of disease in smokers and former smokers: a review. Int J Clin Pract. 2009; 63: 1634–41.

  25. Hastie CE, Haw S, Pell JP. Impact of smoking cessation and lifetime exposure on C-reactive protein. Nicotine Tob Res. 2008; 10:637-42.

  26. Ramírez MM, Sánchez C. Relación entre los niveles séricos de la proteína C reactiva y medidas antropométricas; una revisión sistemática de los estudios realizados en Suramérica. Nutr Hosp. 2012; 27:971-7.

  27. Brooks GC, Michael J. Blaha MJ, Blumenthal RS. Relation of Creactive protein to abdominal adiposity. Am J Cardiol. 2010; 106:56 – 61.

  28. Aronson D, Goldberg A, Roguin A, Petcherski S, Rimer D, Gruberg L, et al. Effect of obesity on the relationship between plasma C-reactive protein and coronary artery stenosis in patients with stable angina. Atherosclerosis. 2006; 185:137-42.

  29. Rocha VZ, Libby P, Obesity, inflammation, and atherosclerosis. Nat Rev Cardiol. 2009; 6: 399-409.

  30. Bays H, Dujovne CA. Adiposopathy is a more rational treatment target for metabolic disease than obesity alone. Curr Atheroscler Rep. 2006, 8:144–56.

  31. Guzmán-Flores JM, López-Briones .Células de la inmunidad innata y adaptativa en la diabetes mellitus tipo 2 y obesidad. Gac Med Mex.2010; 148:381-9.

  32. Androulakis E, Tousoulis D, Papageorgiou N, Latsios G, Siasos G, Tsioufis C, et al. Inflammation in hypertension: current therapeutic approaches. Curr Pharm Des. 2011; 17:4121-31.

  33. Yu B, Wang S, Peng D, Zhao S. HDL and immunomodulation: an emerging role of HDL against atherosclerosis. Immunol Cell Biol. 2010; 88: 285–90.

  34. Sala F, Catapano AL, Norata GD. High density lipoproteins and atherosclerosis: emerging aspects. J Geriatr Cardiol. 2012; 9: E1- E7.

  35. Alber HF, Wanitschek MM, de Waha S, Ladurner A, Suessenbacher A, Dörler J, et al. High-density lipoprotein cholesterol, Creactive protein, and prevalence and severity of coronary artery disease in 5641 consecutive patients undergoing coronary angiography. Eur J Clin Invest 2008; 38: 372–80.




2020     |     www.medigraphic.com